Neuland Laboratories Reports Rs.1107.2 Crores Revenue for H1 FY27 and Invests in Kakinada Expansion
Q2 FY27 revenue at Rs.457.2 Crores amid market fluctuations; new peptide facility commissioned and R&D center planned for early next year
Neuland Laboratories Limited announced Rs.457.2 Crores revenue for Q2 FY27 and Rs.1107.2 Crores for H1 FY27, driven by commercial CMS molecules and GDS specialty portfolio. The company reported EBITDA of Rs.104.6 Crores with a 22.9% margin in Q2, while profit after tax was Rs.51.1 Crores. Neuland undertook capital investments totaling Rs.261 Crores and acquired 134 acres in Kakinada for future expansion, with plans to inaugurate a new R&D center early next year.
Neuland Laboratories Limited
Earnings Call Transcript
Neuland Laboratories Limited reported total income of Rs.457.2 Crores for Q2 FY27 and Rs.1107.2 Crores for the first half of FY27, supported by commercial CMS molecules and contributions from its GDS business. The company reported an EBITDA margin of 22.9% and a net profit of Rs.51.1 Crores in Q2.
The quarter witnessed a decline in total income compared to Rs.516.1 Crores in Q2 FY26, with gross margin slightly decreasing to 59.4%. EBITDA stood at Rs.104.6 Crores (22.9% margin), while profit after tax was Rs.51.1 Crores. Earnings per share were Rs.39.85.
Input cost pressures rose due to geopolitical tensions affecting raw materials and logistics. Working capital days increased to 104 compared to 84 in the previous quarter. Capital expenditure for H1 FY27 was Rs.261 Crores, with free cash flow of Rs.99 Crores and a net negative debt position of Rs.208 Crores.
Neuland's CEO explained the inherent lumpiness in CDMO revenue reflecting customer molecule development timelines. CMS commercial molecules remain a key revenue driver, supplemented by the Prime portfolio in GDS. The company witnessed strong proposal activity, signaling potential future growth.
The GDS segment filed two DMFs for Fezolinetant and Ivacaftor, strengthening its portfolio. Neuland commissioned a new peptide block at Unit One and plans to inaugurate a process R&D center in Genome Valley by early next year.
The company acquired 134 acres of land at Kakinada, Andhra Pradesh, providing scope for long-term capacity expansion and strategic flexibility in response to customer demand.
Highlights
- Q2 FY27 total income: Rs.457.2 Crores vs Rs.516.1 Crores in Q2 FY26.
- H1 FY27 total income: Rs.1107.2 Crores vs Rs.816.7 Crores in H1 FY26.
- Q2 FY27 gross margin: 59.4%; EBITDA: Rs.104.6 Crores with 22.9% margin.
- Q2 FY27 profit after tax: Rs.51.1 Crores; EPS: Rs.39.85 per share.
- Input cost pressures from geopolitical conflicts impacted raw materials and logistics costs.
- Working capital increased to 104 days; capital expenditure at Rs.261 Crores in H1 FY27 with free cash flow of Rs.99 Crores and net debt negative Rs.208 Crores (cash surplus). |Acquired 134 acres land in Kakinada for future expansion plans.
Key Data Snapshot
What happened
- Neuland Laboratories reported Rs.457.2 Crores revenue in Q2 FY27 and Rs.1107.2 Crores in H1 FY27.
- The revenues were primarily driven by commercial CMS molecules and the Prime portfolio within GDS.
- The company reported EBITDA of Rs.104.6 Crores with a margin of 22.9% and net profit of Rs.51.1 Crores in Q2 FY27.
- Capital expenditure for the first half of FY27 was Rs.261 Crores, reflecting ongoing investment.
- Neuland acquired approximately 134 acres of land in Kakinada, Andhra Pradesh, to support future expansion plans.
Key details
- Gross margin for Q2 FY27 stood at 59.4%, slightly below the 60.1% in Q2 FY26.
- Earnings per share for Q2 FY27 were Rs.39.85.
- Working capital days increased to 104 compared to 84 days in the previous quarter.
- Free cash flow for H1 FY27 was Rs.99 Crores, while net debt was negative Rs.208 Crores indicating net cash position.
- Input costs increased due to geopolitical tensions impacting raw material prices and logistics costs.
Operational performance
- Commercial molecules in CMS and specialty portfolio products in GDS contributed materially to revenues.
- Two DMFs were filed during the period for Fezolinetant and Ivacaftor, strengthening the GDS portfolio.
- New peptide block commissioned at Unit One with encouraging traction.
- Process R&D center at Genome Valley, Hyderabad, expected to be operational by early next year.
Strategic context
- Neuland highlighted the typical lumpiness in CDMO business driven by client molecule development and shipment schedules.
- The company is focused on growing CMS contributions alongside GDS and expanding its customer base, including relationships with big pharma.
- The acquisition of land at Kakinada aims to ensure capacity growth does not constrain future customer opportunities.
Highlights
- Q2 FY27 total income: Rs.457.2 Crores vs Rs.516.1 Crores in Q2 FY26.
- H1 FY27 total income: Rs.1107.2 Crores vs Rs.816.7 Crores in H1 FY26.
- Q2 FY27 gross margin: 59.4%; EBITDA: Rs.104.6 Crores with 22.9% margin.
- Q2 FY27 profit after tax: Rs.51.1 Crores; EPS: Rs.39.85 per share.
- Input cost pressures from geopolitical conflicts impacted raw materials and logistics costs.
- Working capital increased to 104 days; capital expenditure at Rs.261 Crores in H1 FY27 with free cash flow of Rs.99 Crores and net debt negative Rs.208 Crores (cash surplus). |Acquired 134 acres land in Kakinada for future expansion plans.
Disclosures
- Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on Earnings Call Transcript
View allLatest corporate announcements and market updates in Earnings Call Transcript.
Sunrakshakk Industries India Limited Posts INR 265.17 Crores Revenue with 130% PAT Increase in Q2 FY27
Sunrakshakk Industries India Limited reported its Q2 FY27 financial results with revenue of INR 265.17 crores and a profit after tax of INR 16 crores, reflecting year-on-year growth of 119.20% in revenue and 130.10% in PAT, supported by expansion in its FMCG, FMCG intermediates, and edible segments.
Read Full StoryReligare Enterprises Posts INR 4,717 Crores Income and INR 145 Crores Loss After Tax in H1 FY27, Resumes Lending and Strengthens Board
Religare Enterprises Limited has reported consolidated total income of INR 4,717 crores and a loss after tax of INR 145 crores for the half-year ending September 30, 2026, marking a 19% increase in income year-on-year. The company is transitioning from preparation to execution phase by strengthening its board with RBI-approved promoter and shareholder directors, resuming lending through Religare Finvest, and advancing growth in its core financial services and insurance businesses.
Read Full StoryBlack Box Limited Posts Record Q2 FY27 Revenue of INR 1,936 Crores and Expands Order Backlog to $1.04 Billion
Black Box Limited reported its highest-ever quarterly revenue of INR 1,936 crores for Q2 FY27, marking a 22% year-on-year increase, alongside an 88% year-on-year growth in its order backlog, which reached $1.04 billion as of September 2026. Data center order bookings crossed $250 million during H1 FY27, signaling strong momentum in hyperscale digital infrastructure projects.
Read Full Story